latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/kala-pharmaceuticals-raises-134m-in-common-stock-offering-57905833 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Kala Pharmaceuticals raises $134M in common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Kala Pharmaceuticals raises $134M in common stock offering

Kala Pharmaceuticals Inc. raised gross proceeds of $134 million in its common stock offering, including the exercise of the underwriters' option to buy additional shares.

The Watertown, Mass.-based biopharmaceutical company sold a total of 16,979,371 common shares in the offering, including the 979,371 additional common shares in the option closing. The shares were sold at $7.89 each.

J.P. Morgan, BofA Securities and Jefferies acted as joint book-running managers for the offering, while Wedbush PacGrow, Oppenheimer & Co. and H.C. Wainwright & Co. acted as co-managers.

Kala Pharmaceuticals develops therapies for eye diseases. Its drug KPI-121, which was previously rejected by the U.S. Food and Drug Administration, was recently shown to benefit dry eye disease patients in a late-stage clinical trial called Stride 3.